$TARS 8-K SEC Filings

Filed On	Filing
10 Sep 2026	8-K: Completion of Acquisition or Disposition of Assets; Other Events Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care September 4, 2026 Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underl...
06 Aug 2026	8-K: Results of Operations and Financial Condition
06 Aug 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
06 Aug 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
13 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation
08 Jul 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
29 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
06 May 2026	8-K: Results of Operations and Financial Condition
23 Feb 2026	8-K: Results of Operations and Financial Condition
18 Feb 2026	8-K: Departure/Election of Directors or Officers; Compensation
12 Jan 2026	8-K: Regulation FD Disclosure
04 Nov 2025	8-K: Results of Operations and Financial Condition
06 Aug 2025	8-K: Results of Operations and Financial Condition
18 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
01 May 2025	8-K: Results of Operations and Financial Condition
18 Mar 2025	8-K: Other Events
13 Mar 2025	8-K: Entry into a Material Definitive Agreement; Other Events
25 Feb 2025	8-K: Results of Operations and Financial Condition
17 Jan 2025	8-K: Departure/Election of Directors or Officers; Compensation
13 Jan 2025	8-K: Regulation FD Disclosure

Comments